Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.64 |
| ▸ | CA9 | Q16790 | 5/20 | 0.64 |
| ▸ | CA1 | P00915 | 5/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.64 |
| ▸ | CA4 | P22748 | 3/20 | 0.64 |
| ▸ | CA6 | P23280 | 3/20 | 0.64 |
| ▸ | CA5A | P35218 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.64 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CA11 | O75493 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27976238 | 0.82 | CA2 (0.39) | CA2CA9CA1CA12CA4 | |
| SCHEMBL282413 | 0.78 | CA2 (1.00) | CA2CA9CA1CA12CA4 | |
| SCHEMBL3500987 | 0.76 | CA2 (0.95) | CA2CA9CA1CA12CA4 | |
| SCHEMBL6507990 | 0.76 | CA2 (0.64) | CA2CA9CA1CA12CA4 | |
| SCHEMBL11169964 | 0.76 | CA2 (0.64) | CA2CA9CA1CA12CA4 | |
| Hydrochloric Acid SCHEMBL2987404 | 0.76 | CA2 (0.95) | CA2CA9CA1CA12CA4 | |
| SCHEMBL9860007 | 0.73 | CA2 (0.59) | CA2CA9CA1CA12CA4 | |
| SCHEMBL21267685 | 0.73 | CA2 (0.59) | CA2CA9CA1CA12CA4 | |
| SCHEMBL11623991 | 0.71 | HSD11B1 (0.42) | CA2CA9CA1CA12CA4 | |
| SCHEMBL9080992 | 0.71 | CA2 (0.52) | CA2CA9CA1CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9511341-B2 | Method for preparing acetazolamide sodium powder | Sunny Pharmtech Inc. (TW) | 2016-12-06 | — | — | US | disclosed |
| US-20150061169-A1 | METHOD FOR PREPARING ACETAZOLAMIDE SODIUM POWDER | SCI PHARMTECH, INC. (TW) | 2015-03-05 | — | — | US | disclosed |
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| CN-1022242-C | Method of synthesizing 2-amino-5-sulfo-1,3,4-thiadiazole | INST OF CHEMICAL INDUSTRY OF S (CN) | 1993-09-29 | — | — | CN | disclosed |
| CN-1022242-C | Method of synthesizing 2-amino-5-sulfo-1,3,4-thiadiazole | INST OF CHEMICAL INDUSTRY OF S (CN) | 1993-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | CA2 1243/4885CA9 1314/4885CA1 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.